Biotechnology AIM Immunotech FDA Lifts Hold, Stock Surges 25%By MohamedMis2July 29, 2023 In a significant development, the FDA has recently lifted its hold on AIM Immunotech. Resulting in a remarkable 25% surge…
Biotechnology AIM ImmunoTech Ovarian Cancer Trial Giving Positive ResultsBy MohamedMis2July 29, 2023 In a recent phase 1/2 clinical trial, AIM ImmunoTech has announced encouraging results from its study involving ovarian cancer patients.…
Drug Manufacture 16% Faster MorphoSys Phase 3By MohamedMis2July 12, 2023 MorphoSys is making significant strides in its Phase 3 myelofibrosis program, completing it 16% faster than expected [1]. This is…
